Synthesis and pharmacological activity of thiourea derivatives of 1,7,8,9-tetramethyl-4-azatricyclo [5.2.1.02,6]dec-8-ene-3,5-dione

Letters in Drug Design and Discovery

Volumn 6, Issue 6, 2009, Pages 445-450

  Struga, Marta ^a   Kossakowski, Jerzy ^a   Kozioł, Anna E ^b   Lis, Tateusz ^c   Ķdzierska, Ewa ^d   Fidecka, Sylwia ^d  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Pharmacological activity; Thiourea derivatives; X ray analysis

Indexed keywords

1 (1 PHENYL ETHYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (2 PHENYL ETHYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (3,4 DICHLOROPHENYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (4 CHLOROPHENYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 ,6]DEC 8 EN 4 YL)THIOUREA; 1 (4 IODOPHENYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (4 METHOXYPHENYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 ,6]DEC 8 EN 4 YL)THIOUREA; 1 (ALLYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (BENZOYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (PHENYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1 (PHENYLMETHYL) 3 (1,7,8,9 TETRAMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 EN 4 YL)THIOUREA; 1,7,8,9 TETRAMETHYL 4 AZATRICYCLO[5.2.1.0 2,6]DEC 8 ENE 3,5 DIONE; 5 HYDROXYTRYPTOPHAN; SEROTONIN RECEPTOR; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 69549120492     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018009789057517     Document Type: Article

References (44)

1. Venkatachalam, T.K; Mao, C.; Uckun, F.M. Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds. Bioorg. Med. Chem., 2004, 12, 4275-4284.
2. Bloom, J.D.; Dushin, R.G; Curran, K.J; Donahue, F.; Norton, E.B.; Terefenko, E.; Jones, T.R; Ross, A.A.; Feld, B.; Lang, S.A.; Di-Grandi, M. J. Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMV. Bioorg. Med. Chem., 2004, 14, 3401-3406.
3. Seth, P.P.; Ranken, R.; Robinson, D.E.; Osgood, D.E.; Risen, L.M.; Rodgers, E.L.; Migawa, M.T.; Jefferson, E.A.; Swayze, E.E. Aryl urea analogs with broad-spectrum antibacterial activity. Bioorg. Med. Chem., 2004, 14, 5569-5572.
4. Lee, J.; Lee, J.; Kang, M.; Shin, M.; Kim, J.M.; Kang, S.U.; Lim, J.O.; Choi, H.K.; Suh, Y.G.; Park, H.G.; Oh, U.; Kim, H.D.; Park, Y.H.; Ha, H.J.; Kim, Y.H.; Toth, A.; Tran, R.; Pearce, L.V.; Lundberg, D.J.; Blumberg, P.M. N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl] thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor. J. Med. Chem., 2003, 46, 3116-3126.
5. 2B receptor antagonist with improved affinity, selectivity, and oral activity. J. Med. Chem., 1995, 25, 2524-2530.
6. Nozulak, J.; Kalkman, H.O.; Floerscheim, P.; Hoyer, D.; Schoeffer, P.; Buerki, H.R. (+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo [1,7- bc][2,6]-naphthyridine: a 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity. J. Med. Chem., 1995, 38, 28-33.
7. Forbes, I.T.; Jones, G.E.; Murphy, O.E.; Holland, V.; Baxter, G.S. N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist. J. Med. Chem., 1995, 38, 855-857.
8. Fludzinski, P.; Wittenauer, L.A.; Schenck, K.W.; Cohen, M.L. 2,3-Dialkyl(dimethylamino) indoles: interaction with 5HT1, 5HT2, and rat stomach fundal serotonin receptors. J. Med. Chem., 1986, 29, 2415-2418.
9. Audia, J.E.; Evrard, D.A.; Murdoch, G.R.; Droste, J.J.; Nissen, J.S.; Schenck, K.W.; Fludziski, P.; Lucaites, V.L.; Nelson, D.L.; Cohen, M.L. Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus. J. Med. Chem., 1996, 39, 2773-2780.
10. Corne, S.J.; Pickering, R.W.; Warner, B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br. J. Pharmacol., 1963, 20,106-120.
11. Corne, S.J.; Pickering, R.W. A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacology, 1967, 11, 65-68.
12. Peroutka, S.J.; Lebovitz, R.M.; Snyder, S.H. Two distinct central serotonin receptors with different physiological functions. Science, 1981, 212, 827-829. (Pubitemid 11069388)
13. Colpaert, F.C.; Janssen, P.A. The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology, 1983, 22, 993-1000.
14. Green, A.R.; O'Shaughnessy, K.; Hammond, M.; Schachter, M.; Grahame-Smith, D.G. Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology, 1983, 22, 573-578.
15. Goodwin, G.M; Green, A.R. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br. J. Pharmacol., 1985, 84, 743-753.
16. Darmani, N.A.; Martin, B.R.; Glennon, R.A. Withdrawal from chronic treatment with (+/-)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice. Eur. J. Pharmacol., 1990, 186, 115-118.
17. Darmani, N.A.; Martin, B.R.; Pandy, U.; Glennon, R.A. Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol. Biochem. Behav., 1990, 36, 901-906.
18. Darmani, N.A.; Martin, B.R.; Glennon, R.A. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+/- )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J. Pharmacol. Exp. Ther., 1992, 262, 692-698.
19. Fantegrossi, W.E.; Kiessel, C.L.; Leach, P.T.; Van Martin, C.; Karabenick, R.L.; Chen, X.; Ohizumi, Y.; Ullrich, T.; Rice, K.C.; Woods, J.H. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology, 2004, 173, 270-277. (Pubitemid 38703800)
20. Lucki, I.; Nobler, M.S.; Frazer, A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J. Pharmacol. Exp. Ther., 1984, 228, 133-139. (Pubitemid 14223392)
21. Handley, S.L.; Singh, L. The modulation of head-twitch behaviour by drugs acting on beta-adrenoceptors: evidence for the involvement of both beta 1- and beta 2-adrenoceptors. Pharmacology, 1986, 7, 320-324. (Pubitemid 16131117)
22. Ortmann, R.; Biscoff, S.; Radeke, E.; Bueche, O.; Delini-Stula, A. Correlation between different measures of antiserotonin activity of drugs. Naunyn Schmiedeberg's Arch. Pharmacol., 1982, 321, 265-270.
23. Ding, J.; Das K.; Moereels, H.; Kaymans, L.; Andries, K.; Janssen, P.A.J.; Hughes, S.H.; Arnold E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol., 1995, 2, 407-415.
24. De Clerq, E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco, 1999, 54, 26-45. (Pubitemid 29187015)
25. Koch K.R. New chemistry with old ligands: N-alkyl- and N,N-dialkyl-N-acyl(aroyl)thioureas in coordination, analytical and process chemistry of the platinum group metals. Coord. Chem. Rev., 2001, 473, 216-217.
26. Vest, P.; Schuster, M.; Konig, K.H. Solvent Extraction of Gold with N-substituted Benzoylthiourea. Fresenius J. Anal. Chem., 1991, 341, 566-568.
27. 6] salts, where L is ethylene- or trimethylene-thiourea, and M is Si, Ge or Sn. Five Te(II) complexes with a novel type of structure linked together by unusual N - H - F hydrogen bonds. Polyhedron, 2004, 23, 3021-3032.
28. Konig, K.H.; Schuster, M.; Schneeweis, G.; Steinbrech, B. On the chromatography of metal chelates XIV. Thin-layer-chromatography of N,N-dialkyl-N'-benzoylthiourea-chelates. Fresenius Z. Anal. Chem., 1984, 319, 66-69.
29. Bombicz, P.; Mutikainen, I.; Krunks, M.; Leskela, T.; Madarasz, J.; Niinist, L. Synthesis, vibrational spectra and X-ray structures of copper(I) thiourea complexes. Inorg. Chim. Acta, 2004, 357, 513-525.
30. Emen, M.F.; Arslan, H.; Kulcu, N.; Florke, U.; Duran, N. Synthesis, characterization and antimicrobial activities of some metal complexes with N '-(2-chloro-benzoyl)thiourea ligands: The crystal structure of fac-[CoL3] and cis-[PdL2]. Polish J. Chem., 2005, 79, 1615-1626.
31. Struga, M.; Kossakowski, J. Synthesis of 4-Amino-1,7,8,9-tetramethyl-4- aza-tricyclo [5.2.1.02,6]dec-8-ene-3,5-dione. Molbank, 2007, M534.
32. Cox, B.; Lomax, P. Pharmacological studies on the central regulation of body temperature. Annu. Rev. Pharmacol. Toxicol., 1997, 17, 341-353.
33. Ulugol, A.; Karadag, H.C.; Dokmeci, D.; Al.-Khatib, I.; Dokmeci, I. The protective effect of moclobemide against hypoxia-induced lethality in mice is not due to a decrease in body temperature. Pharmacol. Biochem. Behav., 1995, 51, 245-247.
34. Gao, B.; Jr Ducan, W.C.; Wehr, T.A. Clorgyline-induced reduction in body temperature and its relationship to vigilance states in Syrian hamsters. Neuropsychopharmacology, 1991, 4, 187-1897.
35. Adell A.; Bigg T.A.; Myers R.D. Action of harman (1-methyl-β- carboline) on the brain: Body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology, 1996, 35, 1101-1107.
36. Oxford Diffraction. CrysAlis CCD and CrysAlis RED. Oxford Diffraction, Wroclaw, Poland, 2001.
37. Sheldrick, G. M. A short history of SHELX. Acta Cryst., 2008, A64, 112-122.
38. Vogel, G.H.; Vogel, W.H. Drug Discovery and Evaluation. Pharmacological Assays. Springer-Verlag: Berlin, 1997.
39. Litchfield, L.T.; Wilcoxon, F. Simplified method of evaluating dose effect experiments. J. Pharmacol. Exp. Ther., 1949, 96, 99-113.
40. Koster, R.; Anderson, M.; DeBeer, E.J. Acetic acid for analgesic screening. Fed. Proc., 1959, 18, 412-416.
41. Gross, F.; Tripod, J.; Meir, R. Zur pharmakologischen charakterisierung des schalafmittels doriden. Schweiz. Med. Wochschr., 1995, 85, 305-309.
42. Boissier, J.R.; Tardy, J.; Diverres, J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basel.), 1960, 3, 81-84.
43. Corne, S.J.; Pickering, R.W.; Werner, B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br. J. Pharmacol., 1963, 20, 106-120.
44. Pauwels R.; Balzarini J.; Baba M.; Snoeck R.; Schols D.; Herdewijn P.; Desmyster J.; De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods, 1998, 20, 309-321.